Palmitoyl Dipeptide-5 Diaminohydroxybutyrate (Matrixyl Morphomics)

Research-Grade

Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, marketed under the trade name Matrixyl Morphomics by Sederma (Croda International), represents the latest evolution of the Matrixyl peptide family. Unlike earlier Matrixyl variants that focused primarily on collagen I and III stimulation, Matrixyl Morphomics was designed to address the morphological changes in the dermal-epidermal junction (DEJ) and the elastic fiber network that accompany intrinsic and photoaging. The active molecule is a dipeptide conjugated to a palmitoyl chain and a diaminohydroxybutyrate moiety, engineered to penetrate the stratum corneum and engage specific signaling cascades in dermal fibroblasts. The peptide's mechanism centers on upregulation of TGF-beta signaling and, critically, fibrillin-1 expression. Fibrillin-1 is the structural glycoprotein that forms the scaffold of oxytalan and elaunin microfibrils in the papillary dermis — the fine elastic fiber network that anchors the DEJ and provides skin resilience and elasticity at a structural level distinct from bulk collagen. Age-related decline in fibrillin-1 is a hallmark of both intrinsic aging and UV-induced photoaging, leading to flattening of the DEJ, loss of papillary dermis architecture, and the characteristic laxity and fine wrinkling of mature skin. By restoring fibrillin-1 deposition, Matrixyl Morphomics aims to rebuild the microstructural scaffolding that is lost with age. Sederma's published in vitro data demonstrated upregulation of fibrillin-1 synthesis in human dermal fibroblast cultures and increased TGF-beta-mediated extracellular matrix gene expression at test concentrations. Manufacturer-sponsored clinical evaluations on human subjects showed improvements in skin firmness, elasticity, and wrinkle depth over 56-84 day treatment periods, with profilometric and biomechanical measurements used as endpoints. Independent peer-reviewed replication remains limited, which is typical for newly launched cosmetic peptide actives. The ingredient is INCI-registered and used in luxury anti-aging skincare formulations. Matrixyl Morphomics is positioned as a complement to — not a replacement for — earlier Matrixyl peptides and other cosmetic actives. Where Matrixyl 3000 addresses collagen quantity and inflammatory glycation, Matrixyl Morphomics targets the qualitative architecture of the elastic fiber network and DEJ integrity. In advanced multi-peptide formulations, it is combined with collagen-stimulating peptides (palmitoyl pentapeptide-4, palmitoyl tripeptide-1) and neuromuscular peptides (Argireline) to provide broad-spectrum anti-aging activity across different structural and functional targets.